Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Casi Pharmaceuticals, Cofactor Genomics, Point32Health

NEW YORK – Casi Pharmaceuticals said this week that China's National Medical Products Administration accepted Juventas Cell Therapy's new drug application for CNCT19, an investigational CD-19-directed CAR T-cell therapy for treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The product has also been granted orphan drug designation by the US Food and Drug Administration and breakthrough designation status by the China Center of Drug Evaluation. In a Phase II trial, CNCT19 showed a high level of efficacy with durable remissions and low CAR T-related toxicity. 

Cofactor Genomics said this week that it has opened enrollment to non-small cell lung cancer patients on its ongoing PREDAPT study of its OncoPrism assay as a tool to predict immunotherapy response. The study is already enrolling squamous cell head and neck cancer, and Cofactor ultimately plans to include 11 different solid cancers on the trial. In head and neck cancer, Cofactor says the test has demonstrated it can predict checkpoint inhibitor response with nearly twice the accuracy as PD-L1 expression biomarkers. 

Point32Health, the parent company of Harvard Pilgrim Health Care, and early cancer detection firm Grail said this week that they have expanded their pilot program offering Grail's Galleri multi-cancer blood test at no cost to Harvard Pilgrim members who purchase their insurance on the Maine Health Insurance Marketplace. 

The collaboration aims to collect real-world evidence to assess the impact of Galleri on health care resource utilization and patient-reported outcomes. Announced earlier this year, the first phase made the test available to Point32Health employees. Under the new expansion, eligible MHIM members will be able to join, as well. These individuals will be mailed information on how to participate. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.